ClinicalTrials.gg
Active, not recruitingNCT05221931DCB-HBRUpdated Feb 12, 2026

Drug-Coated Balloon in Patients With High Bleeding Risk

An interventional study of Percutaneous coronary intervention in Coronary Artery Disease, sponsored by Samsung Medical Center. Active, not recruiting at 17 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,359
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Coronary Artery Disease by Samsung Medical Center — 10 open to participants now, 14 under way, none of them phase 3. Coronary Artery Disease · Samsung Medical Center.

Enrollment
8th of 21
1,359 · median 520
Started
2022
with 2 others
No phase
16 of 31
5 open now
Primary completion
2027-11
later than 7 of 13 live
Registered
17th of 31
by date

Among the 31 studies in Coronary Artery Disease by Samsung Medical Center, this one is the 8th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2022, is one of 16 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 17th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

10 of the 31 studies in Coronary Artery Disease by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Coronary Artery Disease by Samsung Medical Center, or all of them as a file.
02

Study summary

DCB-HBR trial is prospective, multi-center, open-label, randomized controlled, noninferiority trial.

The aim of the study is to compare clinical outcomes of drug-coated balloon (DCB) with drug-eluting stent (DES) for treatment of de-novo coronary lesion in patients with high bleeding risk (HBR).

Read the detailed description

Second-generation DES is the standard of care for patients with coronary artery disease who are deemed eligible for percutaneous coronary intervention (PCI). Despite many advantages, DES inevitably accompany disadvantages such as the occurrence of late stent thrombosis and the need for maintaining dual antiplatelet (DAPT) for certain period due to permanent vascular implant, which lead to both increased ischemic and bleeding events.

As an alternative to DES, drug-coated balloon (DCB), a novel treatment strategy, which has benefit of having shorter DAPT maintenance duration due to the absence of metallic scaffolds and polymers, has been introduced. Based on meta-analysis based on many randomized clinical trials (RCT), its use has been established in in-stent restenosis of bare-metal stents (BMS) and DES. Furthermore, recently published RCT demonstrated efficacy and safety of DCB in de-novo coronary lesions in small vessels with reference vessel size\<3.0mm. However, studies exploring the feasibility of DCB in de-novo coronary artery stenosis beyond small vessels are limited. Furthermore, there is scarce data comparing DCB with DES in patients with de-novo coronary artery stenosis and high bleeding risk (HBR), a situation in which long-term maintenance of DAPT is a clinical dilemma. In previous BASKET-SMALL 2 trial, DCB showed noninferiority to DES in patients with de-novo coronary artery stenosis and small vessel disease. However, this trial was conducted in non-HBR patients, and the number of participated patients was insufficient. In another RCT, DEBUT trial exclusively enrolled patients with HBR and de-novo coronary artery stenosis. Although the DEBUT trial showed superiority of DCB angioplasty over implantation of BMS to treat de-novo coronary artery stenosis in patients with HBR, the results could not be applicable in contemporary practice because BMS has been no longer in clinical use. Recently, multiple RCTs have proved short-term DAPT (1-3 months) has comparable efficacy to longer term DAPT in HBR patients using latest second-generation DES.

On this background, the current trial aims to compare clinical outcomes between DCB and DES to treat de-novo coronary artery stenosis in patients with HBR receiving guideline-directed short-term DAPT.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Percutaneous Coronary Intervention
  • De-Novo Coronary Lesion
  • Drug-Coated Balloon
  • High Bleeding Risk
  • Prognosis
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be at least 19 years of age
  2. Subject who is able to understand risks, benefits and treatment alternatives and sign voluntarily.
  3. Patients with at least one lesion with greater than 50% diameter stenosis or fractional flow reserve ≤0.80 requiring revascularization in de-novo coronary artery of reference vessel size ≥2.25 mm
  4. Patients with high bleeding risk: one or more of the criteria listed (1) Adjunctive oral anticoagulation treatment planned to continue after PCI (2) Age ≥ 75 years old (3) Baseline \<11 g/dl (or anemia requiring transfusion during the 4 weeks prior to randomization) (4) Any prior intra-cerebral bleeding (5) Stroke at any time or in the previous 6 months. (6) Hospital admission for bleeding during the prior 12 months (7) Non skin cancer diagnosed or treated \< 3 years (8) Planned daily NSAID (other than aspirin) or for >30 days after PCI (9) Planned surgery that would require interruption of DAPT (within next 12 months) (10) Renal failure defined as calculated \<40 ml/min or on dialysis (11) Hematological disorders ( count \<100,000/mm3 or any coagulation disorder) (12) Severe chronic liver disease defined as patients who have developed any of the following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice (13) Expected non-compliance to prolonged DAPT for other medical reasons

Exclusion criteria

Exclusion Criteria:

  1. Patients unable to provide consent
  2. Patients with known intolerance to aspirin, P2Y12 inhibitors, or components of drug-eluting stents
  3. Patients with angiographic findings of (1) Left main coronary artery disease (2) In-stent restenosis is the cause of target lesion (3) Target lesion in bypass graft (4) True bifurcation lesion that requires upfront 2-stenting
  4. Patients who have non-cardiac co-morbid conditions with \<2 year
  5. Patients who may result in protocol non-compliance (site investigator's medical judgment)
  6. Patients with cardiogenic shock or cardiac arrest
  7. Patients with severe left ventricular systolic dysfunction ( \<30%)
  8. Patients with severe valvular heart disease requiring open heart surgery
  9. Pregnant or lactating women
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,359 participants (actual)

Study arms

  • Active comparator
    DES group

    Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography. In DES group, latest second-generation DES will be used (Ultimaster Tansei) during the index procedure

    Procedure: Percutaneous coronary intervention

  • Experimental
    DCB group

    Patients will be randomized to either the DCB group or the DES group with 1:1 ratio during the index procedure after diagnostic angiography. In DCB group, Agent (Boston Scientific, USA), Prevail (Medtronic, USA), or SeQuent Please, SeQuent Please NEO (B-Braun, Germany) will be used during the index procedure.

    Procedure: Percutaneous coronary intervention

Interventions

  • ProcedurePercutaneous coronary intervention

    1:1 randomization to DES (Ultimaster Tansei) or DCB (Agent \[Boston Scientific, USA\], Prevail \[Medtronic, USA\], or SeQuent Please, SeQuent Please NEO \[B-Braun, Germany\])

06

What researchers measure

Primary outcomes

  1. Target vessel failure (TVF)

    a composite of cardiovascular death, target-vessel myocardial infarction (MI), and clinically indicated target-vessel revascularization (TVR)

    Time frame: 2 years from last patient enrollment

Secondary outcomes

  1. BARC type 2, 3 or 5 bleeding (Major secondary endpoint)

    BARC type 2, 3 or 5 bleeding

    Time frame: 2 years from last patient enrollment

  2. Cardiovascular death

    Cardiovascular death

    Time frame: 2 years from last patient enrollment

  3. All-cause death

    All-cause death

    Time frame: 2 years from last patient enrollment

  4. Target-vessel MI

    Target-vessel MI

    Time frame: 2 years from last patient enrollment

  5. Non-target vessel related MI

    Non-target vessel related MI

    Time frame: 2 years from last patient enrollment

  6. Non-fatal MI

    Non-fatal MI

    Time frame: 2 years from last patient enrollment

  7. Clinically indicated target-lesion revascularization (TLR)

    Clinically indicated target-lesion revascularization (TLR)

    Time frame: 2 years from last patient enrollment

  8. Clinically indicated TVR

    Clinically indicated TVR

    Time frame: 2 years from last patient enrollment

  9. Non-target vessel revascularization

    Non-target vessel revascularization

    Time frame: 2 years from last patient enrollment

  10. Any revascularization

    Any revascularization

    Time frame: 2 years from last patient enrollment

  11. Vessel or stent thrombosis

    definite by Academic Research Consortium (ARC) definition

    Time frame: 2 years from last patient enrollment

  12. Cardiovascular death or target-vessel MI

    Cardiovascular death or target-vessel MI

    Time frame: 2 years from last patient enrollment

  13. Target vessel failure without procedure-related MI

    a composite of cardiovascular death, target-vessel myocardial infarction (MI) without procedure-related MI, and clinically indicated target-vessel revascularization (TVR)

    Time frame: 2 years from last patient enrollment

  14. Target lesion failure (TLF)

    a composite of cardiovascular death, target-vessel MI, and clinically indicated TLR

    Time frame: 2 years from last patient enrollment

  15. Cardiovascular death, target-vessel MI, or vessel or stent thrombosis

    Cardiovascular death, target-vessel MI, or vessel or stent thrombosis

    Time frame: 2 years from last patient enrollment

  16. All-cause death, non-fatal MI, or any revascularization

    All-cause death, non-fatal MI, or any revascularization

    Time frame: 2 years from last patient enrollment

  17. Bleeding according to BARC definition

    Bleeding according to BARC definition

    Time frame: 2 years from last patient enrollment

  18. Bleeding according to TIMI definition

    Bleeding according to TIMI definition

    Time frame: 2 years from last patient enrollment

  19. Cerebrovascular accident (CVA)

    Ischemic stroke, Hemorrhagic stroke, Transient ischemic attack (TIA)

    Time frame: 2 years from last patient enrollment

  20. Target vessel failure (TVF) at Extended Follow-up

    a composite of cardiovascular death, target-vessel myocardial infarction (MI), and clinically indicated target-vessel revascularization (TVR) at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  21. BARC type 2, 3 or 5 bleeding (Major secondary endpoint) at Extended Follow-up

    BARC type 2, 3 or 5 bleeding at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  22. Cardiovascular death at Extended Follow-up

    Cardiovascular death at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  23. All-cause death at Extended Follow-up

    All-cause death at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  24. Target-vessel MI at Extended Follow-up

    Target-vessel MI at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  25. Non-target vessel related MI at Extended Follow-up

    Non-target vessel related MI at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  26. Non-fatal MI at Extended Follow-up

    Non-fatal MI at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  27. Clinically indicated target-lesion revascularization (TLR) at Extended Follow-up

    Clinically indicated target-lesion revascularization (TLR) at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  28. Clinically indicated TVR at Extended Follow-up

    Clinically indicated TVR at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  29. Non-target vessel revascularization at Extended Follow-up

    Non-target vessel revascularization at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  30. Any revascularization at Extended Follow-up

    Any revascularization at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  31. Vessel or stent thrombosis at Extended Follow-up

    definite ㅍessel or stent thrombosis at Extended Follow-up by Academic Research Consortium (ARC) definition

    Time frame: 4 years from last patient enrollment

  32. Target vessel failure without procedure-related MI at Extended Follow-up

    a composite of cardiovascular death, target-vessel myocardial infarction (MI) without procedure-related MI, and clinically indicated target-vessel revascularization (TVR)

    Time frame: 4 years from last patient enrollment

  33. Cardiovascular death or target-vessel MI at Extended Follow-up

    Cardiovascular death or target-vessel MI at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  34. Target lesion failure (TLF) at Extended Follow-up

    Target lesion failure (TLF) at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  35. Cardiovascular death, target-vessel MI, or vessel or stent thrombosis at Extended Follow-up

    Cardiovascular death, target-vessel MI, or vessel or stent thrombosis at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  36. All-cause death, non-fatal MI, or any revascularization at Extended Follow-up

    All-cause death, non-fatal MI, or any revascularization at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  37. Bleeding according to BARC definition at Extended Follow-up

    Bleeding according to BARC definition at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  38. Bleeding according to TIMI definition at Extended Follow-up

    Bleeding according to TIMI definition at Extended Follow-up

    Time frame: 4 years from last patient enrollment

  39. Cerebrovascular accident (CVA) at Extended Follow-up

    Ischemic stroke, Hemorrhagic stroke, Transient ischemic attack (TIA)

    Time frame: 4 years from last patient enrollment

07

Study locations

17 sites
08

References and documents

Individual participant data

Plan to share: Yes — After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked

Supporting information: Study protocol, Clinical study report

Time frame: After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked

Access criteria: After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Nov 2027, 64 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 64 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2022
First posted
Feb 3, 2022
StartActual
Jul 29, 2022
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2028
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05221931
Collaborators
Seoul St. Mary's Hospital, Seoul National University Bundang Hospital, Korea University Ansan Hospital, Chonnam National University Hospital, Chung-Ang University Gwangmyeong Hospital, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gyeongsang National University Hospital, Uijeongbu St. Mary Hospital, Keimyung University Dongsan Medical Center, Inha University Hospital, Chungbuk National University, Wonju Severance Christian Hospital, SMG-SNU Boramae Medical Center, Kangbuk Samsung Hospital, Sungkyunkwan University, Ewha Womans University, Korea University Guro Hospital
Responsible party
Joo Myung Lee (Professor, Samsung Medical Center) — Principal investigator
First posted
Feb 3, 2022
Start date
Jul 29, 2022
Primary completion
Nov 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Feb 12, 2026

Study contacts

Joo Myung Lee, MD, PhD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion